STAT

Opinion: Compounding pharmacies need stricter federal oversight

Compounding pharmacies are not bartenders mixing a gin and tonic. They produce essentially new drugs. The regulatory loophole that allows compounders to avoid necessary federal scrutiny must be closed.

Millions of Americans use compounded drugs created by a pharmacist or physician who combines, mixes, or changes a drug’s ingredients to meet individuals’ needs. They trust the 7,500 or so compounding pharmacies that do this work.

That trust is sometimes misplaced. In 2012, for example, contaminated steroid painkillers mass-produced by the now-defunct New England Compounding Center in Framingham, Mass., and sickened more than 750 others . Barry Cadden, the center’s president, and Glenn Chin, a pharmacist,

You’re reading a preview, subscribe to read more.

More from STAT

STAT2 min read
STAT+: Pharmalittle: We’re Reading About Lilly’s Zepbound For Sleep Apnea, The FDA Budget, And More
Eli Lilly reported positive results for Zepbound in obstructive sleep apnea, giving the medication a new edge in the highly competitive obesity market.
STAT1 min read
STAT+: In Large Trial, Guardant Health’s Blood Test Detects Colon Cancer, But Less Reliably At Earliest Or Precancerous Stages
If approved, Guardant Health’s liquid biopsy is likely to be a strong new addition to colorectal cancer screening tools, particularly for patients who currently choose not to get screened.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About An OptumRx Contract, 340B Dispute Resolution, And More
Cardinal Health announced its pharmaceutical distribution contracts with UnitedHealth's OptumRx unit will not be renewed after they expire in June.

Related Books & Audiobooks